These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Respiratory syncytial virus, or RSV, is a common infection among both infants and older people that can lead to dangerous inflammation of the lungs and contributes to up to 240,000 hospitalizations in the U.S. annually. But until this year, there wasn’t a vaccine to protect against the virus. Now, there are several. In May, the FDA approved GSK’s Arexvy for adults over age 60, and followed with approval of Abrysvo from Pfizer for the same age group. In August, the agency approved the same Pfizer vaccine for pregnant women in order to protect newborns. And kids under age two whose moms weren’t vaccinated can now take advantage of Sanofi Pasteur’s Beyfortus, a one-time, injected antibody therapy that the FDA approved in July and improves on the previous treatment that required multiple shots throughout the winter season.

More Must-Reads from TIME

Contact us at

Hydration Made Fun
A Modern Flip Phone
A Saliva Pregnancy Test
More Than a Fast Car
A Breakthrough Bassinet